Thus, the lack of PD-L1 can lead to increased DNA damage accumulation and improved tumor control of PARP inhibition in BRCA1 wild-type tumors, while triggering synthetic lethality to PARP inhibitors in vitro (192). Here, CD274 is linked to neoplasm.